Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127761 · ClinicalTrials.gov registry record
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
A clinical trial of Multiple Myeloma, sponsored by Center for International Blood and Marrow Transplant Research.
- Recruiting
- Registry status
- 544
- Enrollment target
- 1
- Study location
NCT03127761 is a study of Multiple Myeloma that is actively recruiting participants, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 544 participants, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03127761, a study of Multiple Myeloma, is actively recruiting participants, sponsored by Center for International Blood and Marrow Transplant Research.
- RECRUITING
- Registry status
- 544 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients. Thus, although potentially curative, standard risk MM patients have excellent prognoses in the era of novel therapies which reduces the overall benefit of alloHCT. However, because the outcomes for high-risk MM remain poor despite the best available standard therapies (overall survival of 24-36 months), initial data suggest that alloHCT should be explored in this subset.
Conditions Studied
Interventions
- OTHER Allogeneic Hematopoietic Stem Cell Transplant
Study Locations (1)
Minnesota
- Center for International Blood and Marrow Transplant Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2028-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03127761
The ClinicalTrials.gov registry entry for NCT03127761 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 544 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target. The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Hematopoietic Stem Cell Transplant is the first listed.
NCT03127761 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03127761 about?
NCT03127761 is a clinical study titled "Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma". Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients wi...
What is the current status of trial NCT03127761?
This trial is currently recruiting. The enrollment target is 544 participants. The study started on 2017-07-25. Estimated completion is 2028-04.
What conditions does trial NCT03127761 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03127761?
The interventions under investigation include: Allogeneic Hematopoietic Stem Cell Transplant (OTHER).
Who is sponsoring clinical trial NCT03127761?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03127761 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.